The utilization of a unified pharmacophore query in the discovery of new antagonists of the adenosine receptor family

Bioorganic and Medicinal Chemistry Letters

Volumn 10, Issue 1, 2000, Pages 31-34

  Webb, Thomas R ^a   Melman, Neli ^b   Lvovskiy, Dmitriy ^a   Ji, Xiao duo ^b   Jacobson, Kenneth A ^b  

^a ChemBridge Research Laboratories   (United States)

^b Building 8A   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5,9 DIHYDRO 6 METHOXYCARBONYL 9 METHYL 2 PHENYL 1,2,4 TRIAZOLO[5,1 A][2,7]NAPHTHYRIDINE; 9 CHLORO 2 (2 FURYL) 5 PHENYLACETYLAMINO 1,2,4 TRIAZOLO[1,5 C]QUINAZOLINE; ADENOSINE A3 RECEPTOR; ADENOSINE A3 RECEPTOR ANTAGONIST; ADENOSINE RECEPTOR; ADENOSINE RECEPTOR BLOCKING AGENT; L 268605; MRS 1067; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; DRUG RECEPTOR BINDING; DRUG STRUCTURE; EMBRYO; HUMAN; HUMAN CELL; IMMUNOMODULATION; LIGAND BINDING; PHARMACOPHORE; STRUCTURE ACTIVITY RELATION;

ADENOSINE-5'-(N-ETHYLCARBOXAMIDE); DATABASES, FACTUAL; FLAVONOIDS; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); INFORMATION STORAGE AND RETRIEVAL; KINETICS; LIGANDS; MOLECULAR CONFORMATION; QUINAZOLINES; RECEPTOR, ADENOSINE A3; RECEPTORS, PURINERGIC P1; STRUCTURE-ACTIVITY RELATIONSHIP; TRIAZOLES;

EID: 0034598352     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(99)00583-1     Document Type: Article

References (26)

1. Jacobson, K. A.; Van Rhee, A. M. In Purinergic Approaches in Experimental Therapeutics; Jacobson K. A.; Jarvis M. F., Eds.; Wiley: New York, 1997; pp 101-128.
2. Jacobson K.A. Trends Pharmacol. Sci. 19:1998;184.
3. Siddiqi S.M., Ji X.D., Melman N., Olah M.E., Jain R., Evans P., Glashofer M., Padgett W.L., Cohen L.A., Daly J.W., Stiles G.L., Jacobson K.A. Nucleosides Nucleotides. 15:1996;693.
4. Jacobson M.A., Chakravarty P.K., Johnson R.G., Norton R. Drug Dev. Res. 39:1996;131.
5. Van Muijlwijk-Koezen J.E., Timmerman H., Link R., Van der Goot H., Ijzerman A.P. J. Med. Chem. 41:1998;3994.
6. Moro S., Li A.H., Jacobson K.A.J. Chem. Inf. Comput. Sci. 38:1998;1239.
7. Belardinelli L., Shryock J.C., Zhang Y., Scammells P.J., Olsson R., Dennis D., Milner P., Pfister J., Baker S.P. J. Pharmacol. Exp. Therap. 275:1995;1167.
8. Suzuki F., Shimada J., Mizumoto H., Karasawa A., Kubo K., Nonaka H., Ishii A., Kawakita T. J. Med. Chem. 35:1992;3066.
9. Shimada J., Suzuki F., Nonaka H., Ishii A., Ichikawa S. J. Med. Chem. 35:1992;2342.
10. Sarges R., Howard H.R., Browne R.G., Lebel L.A., Seymour P.A., Koe B.K. J. Med. Chem. 33:1990;2240.
11. Schingnitz G., Küfner-Mühl U., Ensinger H., Lehr E., Kuhn F. J. Nucleosides Nucleotides. 10:1991;1067.
12. Robeva A.S., Woodard R., Jin X., Gao Z., Bhattacharya S., Taylor H.E., Rosin D.L., Linden J. Drug Devel. Res. 39:1996;243.
13. Feoktistov I., Biaggioni I. Pharmacol. Rev. 49:1997;381.
14. Jacobson K.A., Ijzerman A.P., Linden J. Drug Devel. Res. 47:1999;45.
15. See Mason, J. S. In Molecular Similarity in Drug Design; Dean, P. M., Ed.; Blackie Academic and Professional: Glasgow, 1995; Chapter 6, pp. 138-162.
16. Martin Y.C. J. Med. Chem. 35:1992;2145.
17. Kaminski J.J., Rane D.F., Snow M.E., Weber L., Rothofsky M.L., Anderson S.D., Lin S.L. J. Med. Chem. 40:1997;4103.
18. Clark D.E., Willett P., Kenny P.W. J. Mol. Graphics. 11:1993;146.
19. Wang S., Milne G.W.A., Yan X., Posey I., Nicklaus M.C., Graham L., Rice W.G. J. Med. Chem. 39:1996;2047.
20. TM is a product of ChemBridge Corporation of San Diego, CA. This collection has approximately 9600 compounds currently in stock. This collection started from a database of 250,000 compounds that were potentially available from sources throughout the former Soviet Union. Compounds were initially selected by the application of molecular weight limits (≤500), logP limits (≤5), rotatable bond limits and limits for the number of hydrogen bond donor and acceptors using the 'rule of five' guidelines (See Lipinski, C. A.; Lombardo, F.; Dominy, B. W. Adv. Drug Delivery Rev. 1997, 23, 3). The resulting set of compounds was further filtered to remove reactive and other undesirable compounds. Finally a set of representative desirable compounds was selected by medicinal chemistry expertise and checked for pharmacophore diversity in Chem-X.
21. Karton Y., Jiang J.-I., Ji X.-d., Melman N., Olah M.E., Stiles G.L., Jacobson K.A. J. Med. Chem. 39:1996;2293.
22. Kim Y.-C.; Ji, X.-d.; Jacobson K.A. J. Med. Chem. 39:1996;4142.
23. Jacobson M.A., Chakravarty P.K., Johnson R.G., Norton R. Drug Devel. Res. 37:1996;131.
24. Chem-X is a product of Chemical Design, An Oxford Molecular Company, Oxford, England. The July 1998 version running on a Dell Dimension XPS Pro 200n PC was used in this study. The 3-center pharmacophore was used for this study. The 4-center pharmacophore option is also available. Definitions of the pharmacophore geometry and types are available as part of the documentation for this software see http://www.oxmol.com/prods/chem-x/.
25. Jacobson K.A., Park K.S., Jiang J.-l., Kim Y.-C., Olah M.E., Stiles G.L., Ji X.-d. Neuropharmacology. 36:1997;1157.
26. Ji X.-d., Jacobson K.A. Drug Design Discov. 16:1999;89.